| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 64.2 | 72.9 | 58.6 |
| Other income | 3.2 | 3.0 | 2.8 |
| Total income | 67.4 | 75.9 | 61.3 |
| Profit before exceptional items & tax | 11.8 | 16.6 | 8.9 |
| Exceptional items | 0.0 | -2.1 | -0.2 |
| Profit before tax | 11.8 | 14.5 | 8.7 |
| Net profit | 8.8 | 11.0 | 6.6 |
| Operating margin | 17.5% | 19.1% | 14.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +33.30% |
|---|---|
| Net profit, quarter on quarter | -20.00% |
| Revenue, year on year | +9.60% |
BSE results filing, NSE: JAGSNPHARM. Figures extracted from the filing.
Jagsonpal Pharmaceuticals Ltd: key numbers
- Share price
- ₹242.29
- Market cap
- ₹1,598 Cr
- Revenue (annual)
- ₹287.2 Cr
- Net profit (annual)
- ₹43.08 Cr
- P/E (TTM)
- 35.1×Sector 50.4×
- Promoter holding
- 69.05%+1.16% QoQ
- FII holding
- 2.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jagsonpal Pharmaceuticals Ltd
All →Jagsonpal Pharmaceuticals Acquisition Worth ₹46.7 Cr
Jagsonpal Pharmaceuticals Ltd will acquire the Wellness Portfolio of Group Pharmaceuticals Ltd. The transaction involves a total consideration capped at ₹46.7 Crore.
- Value
- ₹46.70 Cr
Jagsonpal Pharmaceuticals Annual General Meeting
Jagsonpal Pharmaceuticals held its 47th Annual General Meeting on September 18, 2026. Shareholders transacted business including adoption of financial statements and director appointments.
Jagsonpal Pharmaceuticals Earnings Call Transcript: Key Takeaways
Jagsonpal reported a strong Q1FY27 with 9% revenue growth and 22% PAT growth, outperforming industry rates. The focus is on higher-margin specialty segments and integrating the Equitas acquisition to enter the hospital channel.
- Call
- Guides 18% growth
Jagsonpal Pharmaceuticals Investor Presentation: Key Takeaways
Jagsonpal Pharmaceuticals reported a strong start to FY27 with revenue up 9% YoY and PAT up 22%. The company completed the Aequitas acquisition to enter the hospital supplies segment.
Jagsonpal Pharmaceuticals Q1 FY27 Results: Net Profit ₹13.2 Cr, Up 22.2% YoY
Jagsonpal Pharmaceuticals Ltd reported revenue from operations of ₹82.2 Cr (+8.7% YoY) and net profit of ₹13.2 Cr (+22.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹13.2 Cr · +22.2% YoY
Jagsonpal Pharmaceuticals Earnings Call: Key Takeaways
Jagsonpal reported Q4 revenue of ₹64cr (up 10% YoY) and FY26 revenue of ₹287cr (up 7%). Strategy focuses on MR productivity and portfolio rejuvenation in Gynaecology and Dermatology.